Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0102

Scientific exchange · Dr. Chloé Xu

25 Aug 2026 · In person · Dr. Chloé Xu, Gustave Roussy · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0102—

Capture insight from this engagement

Location: Gustave Roussy
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Sequencing after progression

Scientific content used

irAE management guide
VTX core scientific deck v3.2

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?

Notes

Scientific exchange with oncology pharmacist at Gustave Roussy. Discussed pd-l1 testing turnaround, sequencing after progression.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 1
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0102

Audit history (0)

All create, update and approval events for this record

No audit events in sample data